Table 3.
Linear regression analysis of baseline microRNAs relative expression to the functional improvement of the SMA patients at 2 months.
| microRNA | R 2 | Intercept | β | p‐value | Motor milestones scale |
|---|---|---|---|---|---|
| miR‐107 | 0.48 | −0.07 | 3.07 | 0.004 | CHOP‐INTEND |
| miR‐142‐5p | 0.47 | 0.13 | 2.95 | 0.005 | CHOP‐INTEND |
| miR‐328‐3p | 0.33 | −2.01 | 5.78 | 0.03 | CHOP‐INTEND |
| miR‐335‐5p | 0.31 | 0.67 | 2.57 | 0.03 | CHOP‐INTEND |
| miR‐423‐3p | 0.37 | −0.28 | 3.91 | 0.02 | CHOP‐INTEND |
| miR‐660‐5p | 0.40 | 0.47 | 2.01 | 0.01 | CHOP‐INTEND |
| miR‐181b‐5p | 0.38 | 0.27 | 0.77 | 0.005 | HINE |
| miR‐378a‐3p | 0.42 | −1.03 | 2.09 | 0.003 | HINE |
| miR‐125a‐5p | 0.38 | −0.06 | 1.20 | 0.005 | HINE |
| miR‐23a‐3p | 0.39 | −2.00 | 3.31 | 0.004 | HINE |
Presented are unstandardised coefficients, model p value and the motor milestone scale used in the analysis. CHOP‐INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE, Hammersmith Infant Neurological Examination Section 2; SMA, spinal muscular atrophy.